OncoMatch/Kidney Cancer (RCC)/VHL
Kidney Cancer (RCC)VHL Clinical Trials
1 recruiting trials·Updated daily from ClinicalTrials.gov
VHL inactivation is the defining molecular event in clear cell renal cell carcinoma (ccRCC), occurring in over 80% of tumors, and leads to constitutive HIF activation and downstream VEGF/mTOR pathway signaling. Belzutifan, a HIF-2α inhibitor, is FDA-approved for VHL disease-associated RCC and for previously treated advanced ccRCC. Trials evaluate belzutifan combinations with TKIs and immunotherapy in both VHL-mutant and VHL-wild-type settings.
Top recruiting
Top recruiting VHL Kidney Cancer (RCC) trials
Ranked by phase and US site count. See all 1 trials matched to your profile →
Other Kidney Cancer (RCC) biomarkers
Browse other molecular targets with active Kidney Cancer (RCC) trials.